A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Chenodiol (CTEXLI)

Bile Acid class · 1 generic manufacturer · 1 ANDAs filed at FDA.

First FDA approval2015-12-28
Generic availableYes · 1 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$31.2M in CY2024 Part D spend613 claims · 103 beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
97 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Chenodiol used for?

Chenodiol is a Bile Acid medication tracked in Medicare Part D.

Is there a generic for Chenodiol?

Yes. 1 ANDAs filed at FDA, 1 generic manufacturers currently shipping.

How much does my plan pay for Chenodiol?

NADAC pricing data not currently available for this drug.

Is Chenodiol on the FDA shortage list?

No. Chenodiol is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Bile Acid3 alternatives in D1
01
Cholic Acid
Brand: CHOLBAM
Lowest NADAC
0Generic mfrs
$9.5MCY24 Part D spend
Compare →
02
Ursodiol
Brand: Urso 250
$0.412Lowest NADAC
13Generic mfrs
$116.3MCY24 Part D spend
Compare →
03
Usodiol
Bile Acid
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.